Cyclin D1 immunohistochemical expression in Sudanese patients affected with prostatic carcinoma in Khartoum State by Hadi, Muaid Ali Obeid et al.
Sudan Journal of Medical Sciences
Volume 13, Issue no. 4, DOI 10.18502/sjms.v13i4.3604
Production and Hosting by Knowledge E
Research Article
Cyclin D1 Immunohistochemical Expression in
Sudanese Patients Affected with Prostatic
Carcinoma in Khartoum State
Muaid Ali Obeid Hadi, Albadawi abdelbagi Talha, Ali Seed Ahmed, and
Abdalraheem Ali Babiker
Department of Histopathology and Cytology, Faculty of Medical Laboratory Sciences, University
of Gezira, Wad Madani, Sudan
Abstract
Prostatic carcinoma is a common public health problem in aging people. Cyclin D1
proto-oncogene is an important regulator of G1 to S phase progression in many
different cell types. It is believed to play an important role in both tumorigenesis and
grading of many cancers including prostatic carcinoma; high levels of these proteins
have been reported in certain human malignancies and have been implicated in
aberrant cell division and dysregulated tumor growth. The aims of this study was
to examine the immunohistochemical expression of Cyclin D1 in prostatic carcinoma
and to demonstrate the association or relation between Cyclin D1 expressions and
to determine the aggressiveness of the malignant tumors by Gleason Score. In this
study, 50 samples, 25 cases of prostatic cancer and 25 cases of benign prostatic
tissues, were studied for Cyclin D1 expression using an immunohistochemical
technique which was performed on routinely processed, formalin-fixed, and paraffin-
embedded tissues; the tissues were then sectioned into thickness of (3–5 µm) with
rotary microtome instrument, and immunohistochemical expression of Cyclin D1 was
evaluated in all cases. All of the primary human prostatic cancer samples revealed
in different ranges of intensity from weak (+1), moderate (+2) to strongly positive
nuclear staining (+3) for Cyclin D1. In this study, we revealed no nuclear staining in
the benign prostatic hyperplasia (PBH) disease (+0) in 21 cases (84%), and 4 cases
(16%) were ranged in different color intensity; 3 (12%) were weak (1+) and 1 (4%)
wasmoderate (2+), while prostatic cancer caseswere also evaluated in different color
intensity; 13 cases (52%) were (+3), 7 (28%) were (+2), 3 were (12%) were (+1),
and only two (8%) were negative. There was no significance correlation between
Gleason’s score and the intensity of Cyclin D1 expression. Conclusively, it can be said
that Cyclin D1 may be helpful in the differentiation between BPH and prostate cancer,
the correlation between the intensity of Cyclin D1 expression and prostatic diseases
was statistically highly significant (p-value = 0.00). The authors recommend to use
Cyclin D1 as a tumor marker to prostatic carcinoma.
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1. Introduction
Prostate cancer (PC) is currently the most common cause of cancer death in men. The
exact cause of developing PC are not known though ageing, ethnicity, and heredity
are important factors involved in the initiation and development of this cancer. Ageing
is considered the most prominent risk factor, with majority of cases being diagnosed
in men between 60 and 70 years of age (Shen and Abate-Shen 2010). Prostate cancer
is the most common type of cancer among the Sudanese men. The first National
Population-based Cancer Registry (NCR) was established in Sudan in 2009. During
2009–2010, 6771 new cancer cases were registered in Khartoum state. Of those, 3646
(53.8%) cases were of women and 3125 (46.2%) were of men. The most commonly
diagnosed cancer among women was breast cancer, followed by leukemia, cervix, and
ovary, and among men, it was prostate cancer, followed by leukemia, lymphoma, oral,
colorectal, and liver (Saeed et al., 2014). The development of PC occurs through the
accumulation of genetic and epigenetic changes, leading to an inactivation of tumor
suppressor genes and activation of oncogenes (De Marzo et al., 2007). These alter-
ations most likely take several decades, and cancer development can be considered
as a continuous transformation from benign cells, cancer precursors, and malignant
cells (Murphy et al., 1994). Cyclin D1 proto-oncogene is an important regulator of G1 to
S phase progression in many different cell types. It is believed to play an important role
in both tumorigenesis and grading of many cancers including prostatic carcinoma; high
levels of these proteins have been reported in certain human malignancies and have
been implicated in aberrant cell division and dysregulated tumor growth (He et al.,
2007).
2. Aim of the Study
Because the role of Cyclin D1 in PC is unobvious, we studied the expression of Cyclin
D1 in prostatic carcinoma and benign prostatic hyperplasia, relationship between Cyclin
D1 expression and different Gleason Score.
3. Material and Methods
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3.1. Samples
Tissue blocks were obtained from 50 specimen of prostatic tissues, 50% of the cases
were previously diagnosed as malignant prostate tissues and 50% were diagnosed as
benign tumor. The specimens were obtained from histopathology section, Al-tyseer
Medical Centre, during the period of April 2017 to May 2018. Patients’ identification
information such as their age, histopathology diagnosis, and malignant tumor grade,
were obtained from patients files.
3.2. Immunohistochemical techniques
The immunohistochemical procedure was done as follows: one section (3–5 µm)
from formalin-fixed, paraffin-embedded tumors were cut and mounted onto adhesion
microscope slides (super-frosted slides, pre-cleaned 1.1 mm-thick 25.75 mm made in
Citotest Labware Manufacturing Co., Ltd., China). Following deparaffinization in xylene,
slides were rehydrated through a graded series of alcohol and were placed in distilled
water. Samples were steamed for antigen retrieval for Cyclin D1 using high PH (9) by
water bath at 95C for 30 min. After washing with PBS for 3 min Endogenous peroxides
activity were blocked with 3% hydrogen peroxide and methanol for 10 min, and after
washingwith PBS for 3 min the Slides were incubatedwith 20 μL of Polyclonal antibody
(anti-human Cyclin D1 PhosphoThr286 IMMUNOTAG) for 40 min at room temperature
in a moisture chamber washed with PBS and adding secondary antibody for 20 min.
After washing with PBS for 3 min, binding of antibodies will be detected, followed by
adding 3, 3 di amino benzidine tetra hydrochloride (DAB) as a chromogen to produce
the characteristic brown stain for the visualization of the antibody/enzyme complex
for up to 5 min. After washing with distal water for 3 min, Slides were counterstained
with hematoxylin (MAYER’S) for one min and then washed in running tap water for
several minutes 7–10 (bluing), then dehydrated and cleaned, mount in DBX. Each slide
was evaluated with investigator, and the results were confirmed by the consultant
histopathologist.
3.3. Histopathological evaluation of cyclin D1 expression
Cyclin D1 expression was graded on the basis of the intensity of staining within
the tumor cells. Nuclear staining was considered positive, and cytoplasmic staining
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in tumor of prostatic tissue. The scoring system used for evaluation of Cyclin D1
expression (Raju et al., 2005) was as follows:
grade 0+ Negative (no staining)
grade1+ Weak (nuclear staining of < 10% cells)
grade2+ Moderate (staining of 20–40% cells)
grade 3+ Strong (staining of ≥ 50–40% cells).
3.4. Data management analysis
Statistical analysis was done using SPSS (statistical package for social sciences), ver-
sion 16.0, computer program. Frequencies mean and Chi-square Test values were cal-
culated.
4. Result
Among the 50 studied cases, 25 (50%) were previously diagnosed as prostatic carci-
noma and 25 (50%) were diagnosed as BPH based on hematoxylin and eosin-stained
sections.
A total number of 50 cases of prostatic adenocarcinoma removed by radical prosta-
tectomy procedure and benign prostatic hyperplasia were studied. The age of the
patients ranged between 40 and 100 years with mean age of 65 years. Most patients
with prostatic carcinoma, that is, 39 (78%) of them, were between the age of 61 and
80 years, 6 (12%) were between 40 and 60 years, and 5 (10%) were between 81 and
100, as indicated in Table 1.
T 1: Risk age group.





The Gleason scoring of the studied prostatic carcinoma cases ranged between 2
and 10. The most prevalent score in the studied cases was Gleason score 4 (24%) as
showed in Table 2.
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T 2: Frequency of prostatic carcinoma cases according to Gleason score.










The Gleason score of the studied prostatic carcinoma cases ranged between 2–5 and
6–10 (Table 3). The most prevalent score in the studied cases was Gleason score 6–10
(52%).




The statistically significant difference in Cyclin D1 expression among prostatic ade-
nocarcinoma, BPH, and BPH+ chronic prostatitis cases with higher expression in carci-
noma cases as shown in Table 4, Pearson chi-square, value = 36.6, df = 6, and p-value
= 0.00 (highly significant).
T 4: Cyclin D1 expression among prostatic adenocarcinoma, BPH, and BPH+ chronic prostatitis cases.
Diagnosis Intensity of Cyclin D1 staining Total
Negative Weak Moderate Strong
Type Prostatic
adenocarcinoma
2 3 7 13 25
BPH 10 0 0 0 10
BPH+ chronic prostatitis 11 3 1 0 15
Total 23 6 8 13 50
Cyclin D1 expression in 25 cases, in prostate adenocarcinoma and according to inten-
sity of Cyclin D1 staining, Strong 3+, moderate 2+, weak 1+, and negative 0, and highest
grade 3+ as shown in Table 5.
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There was a negative significant correlation between Gleason score and staining
intensity for Cyclin D1 (–0.135) and p.v no significant association (0.519), as shown in
Table 6.
T 6: Correlation between intensity of cyclin D1 expression and Gleason score.
Gleason score Intensity Cyclin
D1 expression
Gleason score Pearson Correlation 1 –0.135
Sig. (2-tailed) 0.519
intensity of Cyclin D1
expression
Pearson Correlation –0.135 1
Sig. (2-tailed) 0.519
Figure 1: Clear cell carcinoma, showing strong nuclear cyclin D1 staining, grade 3+ (cyclin D1 Olympus
digital camera).
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Figure 2: Prostatic adenocarcinoma with rounded glands showing strong nuclear Cyclin D1 staining, grade
3+.
Figure 3: Prostatic adenocarcinoma, showing moderate nuclear Cyclin D1 staining, grade 2+.
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Figure 4: Cyclin D1 staining in benign prostate tissue, showing negative staining of the benign prostatic
tissue and the absence of staning in the nucleus grade 0+.
5. Discussion
Prostate cancer is a major public health problem in countries with aging population,
and is now the most commonly diagnosed cancer in men as well as the second leading
cause of male cancer deaths that occurs in 1 out of 6 men (Ferlay et al., 2008). Many
studies have revealed the association of PC with certain abnormalities as Cyclin D1
proto-oncogene, which is an important regulator of G1 to S phase progression in many
different cell types. It is believed to play an important role in both tumorigenesis
and grading of many cancers including prostatic carcinoma (He et al., 2007). Previous
studies have reported regarding the role of Cyclin D1 expression in PC, however, in
the present study, all of the primary human PC samples revealed different ranges
according to the regions of staining intensity fromweak, moderate to strongly positive
nuclear Cyclin D1 staining in 23 out of 25 cases (92%). This study is in contrary to those
observed by Samia et al. who found that in PC, the Cyclin D1 was expressed in 23 of
25 (92%) cases (Samia et al., 2017). The results obtained in the present study was
almost in agreement with the following studies: Ueda et al. in 2001 found that 84.6%
of cases of prostatic carcinoma showed Cyclin D1 expression. These results indicated
that increased expression of Cyclin D1 in malignant prostate tissue (Ueda et al, 2001)
and also Alqahtani et al. in 2015 found that 90% of PC revealed positivity of Cyclin D1.
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The correlation between Cyclin D1 and Gleason grades was not significant (Alqahtani
et al., 2015). Gupta et al. reported that Cyclin D1 expression was seen with higher
frequency in prostatic carcinoma and also observed focally and weak staining may
be seen in benign cases but that had never reached a significant proportion as seen in
carcinoma of the prostate. However, the study observed no significant correlation of
Cyclin D1 expression with Gleason grade (Gupta et al., 2014). Chen et al. notice that
overexpression of Cyclin D1 increases cell growth and tumorigenicity in human PC
(Chen et al., 2004). Hosni et al., in 2013, found that all cases (100%) revealed foci (>
10% of cancer cells) with positive nuclear staining for Cyclin D1 with different grades
ranging from moderate to strong, no significant correlation was found between the
intensity of Cyclin D1 expression and Gleason’s score (Hosni et al., 2013). ÖZBEK et al.
(2000) reportedmore expression of Cyclin D1 in PC samples, but our studywas different
from previous study reported by Shiraishi et al. (1998), who noticed positive nuclear
Cyclin D1 expression in 20 of 66 (30%) studied cases (Shiraishi et al., 1998), and in
same contrast, Kallakury et al. in 1997 found Cyclin D1 positivity in 31 of 140 PC (22%)
of studied cases and also different from that reported by Kallakury et al., 1997, and Han
et al. in 1998 reportedmoderate to strongly positive staining for Cyclin D1 in 12 of the 50
primary PC samples (24%) (Han et al., 1998). We can’t suggest a cause for this obvious
discrepancy, other than difference in the diagnostic approaches. In the present study,
we also observed no significant correlation between Cyclin D1 expression and Gleason
score as shown in Table 6); so, our findingswere quite similar to the results observed by
Samia et al. (2017); Drobniak et al. (2000); Hosni et al. (2013); Fleischmann et al. (2011),
and Nagela et al. (2016) and contrary to that of Comstock et al. (2007), who reported
significant correlation between Cyclin D1 and Gleason score. In this study, BPH revealed
no staining in the epithelial cells (84%), but there was low staining in benign prostatic
hyperplasia with prostatitis to Cyclin D1 staining was congruent to study reported by
Alqahtani et al. (2015), who reported that 84% of PBH showed negativity to Cyclin D1
and Samia et al. reported that in BPH group, only three cases (20%) showed positive
nuclear Cyclin D1 expression (Samia et al. 2017), and also Comstock et al. (2007). But this
study disagrees with Ueda et al. (2001) who found that 53.8% BPH cases were positive
to Cyclin D1. In the present study, we also observed 1 case (4%) of cytoplasmic positive
out of 25 cases; we disagree with Comstock et al. in 2007 who reported that most
tumors showed cytoplasmic restriction of Cyclin D1, and Gupta et al. in 2014 found that
carcinoma cases; 24 cases on the other hand showed both nuclear and cytoplasmic
positivity, whereas 2 cases showed cytoplasmic and 4 cases showed nuclear positivity
only to Cyclin D1 staining and another only nuclear Cyclin D1 staining.
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6. Conclusion
Conclusively, we found that most Cyclin D1 expression in prostate carcinomawere 93%
of cases, while in benign prostatic hyperplasia was 16%, and the correlation between
Cyclin D1 and Gleason score showed negative significant.
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